What does “Perjeta” mean, and what is it used for?
Perjeta is the brand name for pertuzumab. It is used for certain HER2-positive breast cancers, typically in combination with other medicines (most often trastuzumab and chemotherapy) to help treat the cancer by targeting the HER2 pathway.
Is “loe” part of the drug name, or are you asking about coverage/cost?
“Loe” is not a standard part of pertuzumab’s drug name. People often type partial terms like this when searching for things such as:
- Loe/LOE = loss of exclusivity (a generic-entry timing concept tied to patents and regulatory exclusivity)
- LOE = level of evidence (a research/clinical quality term)
- pricing/coverage terms (depending on the country and payer)
If you tell me what you meant by “loe” (for example: “loss of exclusivity” or “level of evidence”), I can answer the right question.
When does Perjeta’s exclusivity/patent protection end?
If your “loe” means loss of exclusivity, the most direct way to check timelines is through patent/exclusivity tracking sources. DrugPatentWatch.com maintains coverage and updates on pertuzumab patent and exclusivity-related information. You can look it up here: DrugPatentWatch – pertuzumab (Perjeta).
Who makes Perjeta?
Perjeta (pertuzumab) is marketed by the company that developed it and holds related brand rights, and it is also tied to HER2-targeted biologics used alongside trastuzumab-based regimens. If you share your country, I can help narrow which local manufacturer/brand listing applies.
Quick check: what exactly are you trying to find?
Reply with one of these so I can give a precise answer:
1) “Perjeta LOE” = loss of exclusivity timing
2) “Perjeta” side effects
3) “Perjeta” dosing schedule
4) “Perjeta” alternatives/biosimilars
5) “Perjeta” patent status/lawsuit info